Hematological Cancers
Hematological Cancers - Related Videos
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
0 Views •
Cited by 52 •
2012
A method to culture an endothelial cell monolayer throughout the entire inner 3D surface of a microfluidic device with microvascular-sized channels (<30 μm) is described. This in vitro microvasculature model enables the study of biophysical interactions between blood cells, endothelial cells, and soluble factors in hematologic diseases.
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
0 Views •
Cited by 10 •
2019
We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
0 Views •
Cited by 6 •
2014
The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
0 Views •
Cited by 59 •
2015
This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
0 Views •
Cited by 25 •
2016
Here we describe a protocol aimed at investigating the impact of aberrant splicing on drug resistance in solid tumors and hematological malignancies. To this goal, we analyzed the transcriptomic profiles of parental and resistant in vitro models through RNA-seq and established a qRT-PCR based method to validate candidate genes.
FAQs
Genetic and epigenetic changes can disturb several linked controls in hematopoietic cells, including proliferation, differentiation, survival, and programmed cell death. When these controls become imbalanced, abnormal populations gain a persistence or growth advantage and accumulate in the marrow, blood, lymph nodes, or other tissues. Studying these changes helps explain disease behavior and supports molecular classification and risk assessment.
Immune evasion allows abnormal blood or lymph cells to persist despite immune regulation, while inflammation can shape the surrounding tissue environment and influence disease biology. Together, these processes connect cancer development with core immunology: they show how altered immune cells escape normal control and how immune-system activity may contribute to disease progression. This relationship also informs immune-based treatment strategies.
The affected cell may be a hematopoietic stem cell or a more mature blood or lymph cell, and that distinction influences which normal functions become disrupted. Changes in stem-cell regulation can affect blood-cell generation broadly, whereas alterations in mature immune cells may produce disease within specific blood or lymph populations. Comparing these stages helps researchers interpret disease classification and immune dysfunction.
Disruption of differentiation can prevent cells from acquiring appropriate mature functions, while altered survival or programmed cell death can allow abnormal cells to persist. Excessive proliferation then increases their representation in blood-forming or immune tissues. Considering these mechanisms together is more informative than examining growth alone because accumulation reflects the combined effects of production, maturation, persistence, and elimination.
Evaluation can combine molecular classification, flow cytometry, cytogenetics, and sequencing rather than relying on a single test. These approaches examine different features of the abnormal population and provide complementary evidence for diagnosis and risk assessment. Using several methods helps characterize the malignancy more precisely, which can support decisions about prognosis and the most appropriate therapeutic strategy.
These approaches help distinguish different forms of disease and estimate risk, adding biological context to the initial diagnosis. Molecular classification and sequencing address molecular features, cytogenetics contributes information about chromosome-level changes, and flow cytometry helps characterize cell populations. Together, the results can clarify disease behavior and guide treatment planning rather than merely confirming that abnormal cells are present.
These treatment approaches are relevant when disease biology and immune-cell features provide actionable targets or therapeutic opportunities. Targeted drugs address selected molecular vulnerabilities, antibody-based therapies use specific recognition, and cellular immunotherapies harness immune cells against malignancy. Their use reflects the growing connection between molecular classification, immune regulation, and individualized treatment in hematological cancer research and care.
They provide a way to study how immune cells are generated, regulated, transformed, and sometimes able to evade immune control. This makes them valuable for investigating immune-cell development and inflammation, while also offering context for antibody-based and cellular immune therapies. Research in this area can therefore connect basic immune mechanisms with diagnostic methods and treatment strategies for blood and lymph malignancies.